Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Prud'Homme, Gérald J ^a,b   Glinka, Yelena ^a,b   Toulina, Anna ^a,b   Ace, Olga ^a,b   Subramaniam, Venkateswaran ^a,b   Jothy, Serge ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; AROMATIC HYDROCARBON RECEPTOR AGONIST; BREAST CANCER RESISTANCE PROTEIN; CELL MARKER; CYCLIN DEPENDENT KINASE 4; CYTOCHROME P450 1A1; ETOPOSIDE; MITOXANTRONE; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; SMALL INTERFERING RNA; STEM CELL FACTOR RECEPTOR; TRANILAST; UNCLASSIFIED DRUG; ANTHRANILIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER STEM CELL; CELL CYCLE ARREST; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; GENE SILENCING; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TRANSCRIPTION INITIATION; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

MUS;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; RECEPTORS, ARYL HYDROCARBON; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 78149487540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013831     Document Type: Article

References (57)

1. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
2. O'Brien CA, Kreso A, Dick JE (2009) Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 19: 71-77.
3. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumourinitiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
4. Winquist RJ, Furey BF, Boucher DM (2010) Cancer stem cells as the relevant biomass for drug discovery. Curr Opin Pharmacol 10: 385-390.
5. Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, et al. (2005) Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 23: 1059-1065.
6. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313.
7. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, et al. (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13(8B): 2236-2252.
8. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drugselected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3: e3077.
9. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101: 14228-14233.
10. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
11. Prud'homme GJ (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87: 1077-1091.
12. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ (2009) Tranilast inhibits the growth and metastasis of mammary carcinoma. Anti- Cancer Drugs 20: 334-345.
13. Subramaniam V, Chakrabarti R, Prud'homme GJ, Jothy S (2010) Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anti-Cancer Drugs 21: 351-361.
14. Konneh M (1998) Tranilast, Kissei Pharmaceuticals. Idrugs 1: 141-146.
15. Furness SG, Whelan F (2009) The pleiotropy of dioxin toxicity - Xenobiotic misappropriation of the aryl hydrocarbon receptor's alternative physiological roles. Pharmacol Ther 124: 336-353.
16. Kerkvliet NI (2009) AHR-mediated immunomodulation: the role of altered gene transcription. Biochem Pharmacol 77: 746-760.
17. Hall JM, Barhoover MA, Kazmin D, McDonnell DP, Greenlee WF, et al. (2010) Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol 24: 359-369.
18. Zhang S, Lei P, Liu X, Li X, Walker K, et al. (2009) The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. Endocr Relat Cancer 16: 835-844.
19. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25.
20. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
21. Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9.
22. Ding XW, Wu JH, Jiang CP (2010) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86: 631-637.
23. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
24. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888.
25. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, et al. (2008) Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 10: R52.
26. McNamee JP, Jurima-Romet M, Kobus SN, Marks GS (1997) cDNA-Expressed human cytochrome P450 isozymes. Inactivation by porphyrinogenic xenobiotics. Drug Metab Dispos 25: 437-441.
27. Denison MS, Nagy SR (2003) Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43: 309-334.
28. Barhoover MA, Hall JM, Greenlee WF, Thomas RS (2010) The AHR regulates cell cycle progression in human breast cancer cells via a functional interaction with CDK4. Mol Pharmacol 77: 195-201.
29. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, et al. (2002) The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8: 22-28.
30. Sládek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorinebased cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49: 309-321.
31. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
32. Tang C, Ang BT, Pervaiz S (2007) Cancer stem cell: target for anti-cancer therapy. FASEB J 21: 3777-3785.
33. Steiniger SC, Coppinger JA, Krüger JA, Yates J, 3rd, Janda KD (2008) Quantitative mass spectrometry identifies drug targets in cancer stem cellcontaining side population. Stem Cells 26: 3037-3046.
34. Chuthapisith S, Eremin J, El-Sheemey M, Eremin O (2010) Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 19: 27-32.
35. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511.
36. Zucchi I, Sanzone S, Astigiano S, Pelucchi P, Scotti M, et al. (2007) The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci U S A 104: 10476-10481.
37. Puga A, Barnes SJ, Dalton TP, Chang C, Knudsen ES, et al. (2000) Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. J Biol Chem 275: 2943-2950.
38. Gomez-Duran A, Carvajal-Gonzalez JM, Mulero-Navarro S, Santiago-Josefat B, Puga A, et al. (2009) Fitting a xenobiotic receptor into cell homeostasis: how the dioxin receptor interacts with TGFbeta signaling. Biochem Pharmacol 77: 700-712.
39. Chang X, Fan Y, Karyala S, Schwemberger S, Tomlinson CR, et al. (2007) Ligand-independent regulation of transforming growth factor beta1 expression and cell cycle progression by the aryl hydrocarbon receptor. Mol Cell Biol 27: 6127-6139.
40. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
41. Ruby CE, Leid M, Kerkvliet NI (2002) 2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NFkappaB/ Rel in dendritic cells: p50 homodimer activation is not affected. Mol Pharmacol 62: 722-728.
42. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, et al. (2008) NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111: 419-427.
43. Casado FL, Singh KP, Gasiewicz TA (2010) The aryl hydrocarbon receptor: regulation of hematopoiesis and involvement in the progression of blood diseases. Blood Cells Mol Dis 44: 199-206.
44. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, et al. (2009) Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One 4: e5722.
45. Fritz WA, Lin TM, Cardiff RD, Peterson RE (2007) The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 28: 497-505.
46. Wang T, Gavin HM, Arlt VM, Lawrence BP, Fenton SE, et al. (2010) Aryl hydrocarbon receptor (AhR) activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA-induced mammary tumors. Int J Cancer (Epub ahead of print).
47. Bencko V, Rames J, Ondrusova M, Plesko I, Jurickova L, et al. (2009) Human exposure to polyhalogenated hydrocarbons and incidence of selected malignancies-central European experience. Neoplasma 56: 353-357.
48. Isaji M, Miyata H, Ajisawa Y (1998) Tranilast: A new application in the cardiovascular field as an antiproliferative drugs. Cardiovascular Drug Reviews 16: 288-299.
49. Holmes DR, Jr., Savage M, LaBlanche JM, Grip L, Serruys PW, et al. (2002) Results of prevention of restenosis with tranilast and its outcomes (PRESTO)- trial. Circulation 106: 1243-1250.
50. Izawa A, Suzuki Ji, Takahashi W, Amano J, Isobe M (2001) Tranilast inhibits cardiac allograft vasculopathy in association with p21(Waf1/Cip1) expression on neointimal cells in murine cardiac transplantation model. Arterioscler Thromb Vasc Biol 21: 1172-1178.
51. Glinka Y, Chang Y, Prud'homme GJ (2006) Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand. Mol Ther 14: 578-587.
52. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2003) In vitro propogation and transcriptional profiling of human mammary stem/ progenitor cells. Genes Dev 17: 1253-1270.
53. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, et al. (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4: e6146.
54. Savouret JF, Antenos M, Quesne M, Xu J, Milgrome E, et al. (2001) 7- ketocholesterol is an endogenous modulator for aryl hydrocarbon receptor. J Biol Chem 276: 3054-3059.
55. Brent PJ (1996) Kappa opioid receptor agonists inhibit sigma-1 (sigma 1) receptor binding in guinea-pig brain, liver and spleen: autoradiographical evidence. Brain Res 725: 155-165.
56. Korah RM, Sysounthone V, Golowa Y, Wieder R (2000) Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Res 60: 733-740.
57. Subramaniam V, Li H, Wong M, Kitching R, Attisano L, Wrana J, et al. (2003) The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer 89: 1538-1544.